271 related articles for article (PubMed ID: 32503344)
1. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
2. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
Adamec I; Jovanović I; Krbot Skorić M; Habek M
Eur J Neurol; 2022 Mar; 29(3):901-904. PubMed ID: 34676950
[TBL] [Abstract][Full Text] [Related]
3. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.
von Essen MR; Chow HH; Holm Hansen R; Buhelt S; Sellebjerg F
Front Immunol; 2023; 14():1249201. PubMed ID: 37744364
[TBL] [Abstract][Full Text] [Related]
4. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Sellner J; Rommer PS
Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
[TBL] [Abstract][Full Text] [Related]
5. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N; Baker D; Kang AS; Pryce G; Marta M; Visser LH; Hofmann WE; Gnanapavan S; Giovannoni G; Schmierer K
Immunology; 2018 Jun; 154(2):253-260. PubMed ID: 29247512
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
8. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S; Ponzano M; Ivaldi F; Signori A; Lapucci C; Casella V; Ferrò MT; Vigo T; Inglese M; Mancardi GL; Uccelli A; Laroni A
CNS Drugs; 2022 Jan; 36(1):83-96. PubMed ID: 34894339
[TBL] [Abstract][Full Text] [Related]
9. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
13. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
14. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
15. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
17. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
Rolla S; De Mercanti SF; Bardina V; Horakova D; Habek M; Adamec I; Cocco E; Annovazzi P; Vladic A; Novelli F; Durelli L; Clerico M
J Neuroimmunol; 2017 Dec; 313():89-91. PubMed ID: 29153614
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
19. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
20. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Havari E; Turner MJ; Campos-Rivera J; Shankara S; Nguyen TH; Roberts B; Siders W; Kaplan JM
Immunology; 2014 Jan; 141(1):123-31. PubMed ID: 24116901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
